RenovoRx is a medical technology company specializing in innovative solutions for targeted cancer treatment. The company operates primarily in the healthcare sector, focusing on the development and commercialization of advanced medical devices for the delivery of chemotherapy. RenovoRx's flagship product, RenovoCath, is a dual balloon infusion catheter designed to deliver chemotherapy directly to the tumor site, enhancing treatment efficacy and minimizing systemic side effects.

RenovoRx serves patients suffering from pancreatic and bile duct cancers, two of the most challenging and deadly forms of cancer. The company is actively involved in clinical trials, including the Phase III TIGeR PaC trial, to validate the effectiveness of its targeted delivery system.

The business model of RenovoRx revolves around the development, patenting, and commercialization of its medical devices. Revenue is generated through the sale of these devices to healthcare providers and institutions involved in cancer treatment. Additionally, the company may receive funding and grants for its research and development efforts.

RenovoRx operates in the U.S. and European markets, where it continues to expand its clinical trials and seek regulatory approvals. The company aims to address the unmet needs in cancer treatment by providing more effective and targeted therapeutic options.

Keywords: targeted chemotherapy, pancreatic cancer, bile duct cancer, dual balloon catheter, RenovoCath, clinical trials, medical devices, healthcare innovation, cancer treatment, U.S. patents.